Hong Kong Department of Health Approves the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

Asieris Pharmaceuticals announced that the Government of Hong Kong Special Administrative Region Department of Health has approved the registration applications for the Uro-G and Uro-V disposable cystoscopic system. Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and counterclockwise. These angles provide doctors with the flexibility to manipulate the lens, allowing them to view the panorama of the bladder while looking directly at the screen, which also reduce blind spots.

The Uro-G also has its own operating orifice, so that doctors don't have to change the equipment frequently. The cystoscope also contains an LED light source at the tip to provide intracavity illumination for enhanced visualization during cystoscopy. The small 12-Fr.

diameter cystoscope with hydrophilic coating of Uro-V ensures ease of insertion and greater patient comfort. Provides the ability to easily and rapidly visualize the entire bladder with a slight coude tip and wide field of view optics. Used together with the handheld Uro-3500 electronic endoscope image processor of unique design, the images collected by the Uro-G and Uro-V can be processed and transmitted to the display screen for image visualization, so that the target tissue, the equipment, and the endoscope image remain in doctors' straight line of sight, facilitating examination.

The integrated, portable design of the cystoscope enables doctors to complete cystoscopy single-handedly, thereby increasing its applicability. Uro-3500, Uro-G and Uro-V were developed by Uroviu Corporation, and both received U.S. Food and Drug Administration (FDA) clearance in 2018 and 2021, respectively. Asieris Pharmaceuticals signed a collaboration agreement with UroViu in May 2021, and obtained the commercialization rights of UroViu's single-use cystoscopy system in China.

The registration applications for Uro-3500 and Uro-G were respectively accepted by the China National Medical Products Administration (NMPA) in July 2022 and February 2023.